CN Patent

CN113350531A — 前列腺特异性膜抗原结合配体偶联物及其应用

Assigned to Shanghai Helixing Pharmaceutical Technology Co ltd · Expires 2021-09-07 · 5y expired

What this patent protects

本发明涉及前列腺特异性膜抗原结合配体偶联物及其应用。具体涉及一种如式I所示的偶联物，以及包括所述偶联物的标记化合物，以及其为显影剂和治疗药物用于诊断及治疗前列腺癌的用途。

USPTO Abstract

本发明涉及前列腺特异性膜抗原结合配体偶联物及其应用。具体涉及一种如式I所示的偶联物，以及包括所述偶联物的标记化合物，以及其为显影剂和治疗药物用于诊断及治疗前列腺癌的用途。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN113350531A
Jurisdiction: CN
Classification: —
Expires: 2021-09-07
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Helixing Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.